Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Ariad Pharmaceuticals, Inc.    ARIA   US04033A1007

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/27/2015 04/28/2015 04/29/2015 04/30/2015 05/01/2015 Date
9.05(c) 8.87(c) 9.23(c) 8.67(c) 9.15(c) Last
6 625 648 6 325 389 9 020 919 8 670 246 7 403 019 Volume
-6.80% -1.99% +4.06% -6.07% +5.54% Change
More quotes
Financials ($)
Sales 2015 153 M
EBIT 2015 -182 M
Net income 2015 -192 M
Finance 2015 80,5 M
Yield 2015 -
Sales 2016 213 M
EBIT 2016 -136 M
Net income 2016 -134 M
Finance 2016 78,3 M
Yield 2016 -
PER 2015 -
PER 2016
EV / Sales 2015 10,7x
EV / Sales 2016 7,70x
Capitalization 1 716 M
More Financials
Company
ARIAD Pharmaceuticals, Inc. operates as an oncology company which engages in the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer.Its products includes Iclusig (ponatinib), Brigatinib (previously known as AP26113), and AP32788.The company was founded... 
Sector
Pharmaceuticals
Calendar
05/07Earnings Release
More about the company
Surperformance© ratings of Ariad Pharmaceuticals, Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ARIAD PHARMACEUTICALS, INC
04/30 ARIAD PHARMACEUTICALS : Reports Updated Clinical Data on Brigatinib in Patients ..
04/29 ARIAD PHARMACEUTICALS : Announces Results of Preclinical Studies on Brigatinib a..
04/29 ARIAD PHARMACEUTICALS : Presents Updated Clinical Data on Brigatinib in Patients..
04/29 ARIAD PHARMACEUTICALS : Entry into a Material Definitive Agreement, Change in Di..
04/29 ARIAD PHARMACEUTICALS : Enters into Settlement Agreement with Sarissa Capital Ma..
04/29 ARIAD PHARMACEUTICALS : Founder, Harvey J. Berger, M.D., to Retire as Chairman a..
04/23 ARIAD PHARMACEUTICALS : to Webcast Conference Call on First Quarter 2015 Financi..
04/22 ARIAD PHARMACEUTICALS : Announces Issuance of Key U.S. Patent on Brigatinib
More news
Sector news : Biopharmaceuticals
03:33p TEVA PHARMACEUTICAL : What does Mylan really think it's worth?
05:45aDJMyriad Genetics Fights Off Threats From Rivals
05/02 EXCLUSIVE - SIEMENS HEALTHCARE UNIT : sources
More sector news : Biopharmaceuticals
News from SeekingAlpha
05/01 NEXT WEEK IN BIOTECH : Earnings Deluge - From GSK And Achillion To Intercept And..
04/29 Ariad chief to retire by end of year
04/06 Iclusig cleared in Canada
02/27 SEEKING ALPHA'S BIOTECH WEEKLY : Achillion Overdone, Sanofi's Toujeo A Go, And M..
02/23 What Sarissa Capital's Proxy Fight Means For Ariad Investors


Comments 
Advertisement
Chart ARIAD PHARMACEUTICALS, INC
Duration : Period :
Ariad Pharmaceuticals, Inc Technical Analysis Chart | ARIA | US04033A1007 | 4-Traders
Full-screen chart
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF